CTOs on the Move

Synexis

www.synexis.com

 
Synexis is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medical Imaging Applications

Medical Imaging Applications LLC is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RoundGlass

RoundGlass is committed to enabling individuals to live their Journey of holistic Wellbeing and Meaningful Living™. The RoundGlass community of associates, portfolio companies, fellows, partners and ambassadors advocate and develop solutions across the RoundGlass holistic Wellbeing Pillars. The RoundGlass Wholistic Wellbeing Pillars: 1. Live – Wellbeing of self: From the right health care decision to celebrating life 2. Learn – Wellbeing of the future: Living with purpose and mastering key qualities 3. Give – Wellbeing of society: Empowering community wellbeing so that all members live with dignity 4. Sustain – Wellbeing of the planet: Meaningful programs that improve the environment

Dogwood Forest Of Alpharetta

Dogwood Forest Of Alpharetta is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MindFirst Health & Fitness

Dedicated to helping people live happier, healthier, more balanced lives by focusing on both mind and body

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.